(0.25%) 5 112.94 points
(0.14%) 38 293 points
(0.32%) 15 979 points
(-1.38%) $82.69
(3.69%) $1.994
(0.10%) $2 349.50
(-0.01%) $27.53
(3.37%) $953.15
(-0.11%) $0.934
(-0.21%) $11.00
(-0.39%) $0.797
(1.74%) $93.47
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.22%
@ $3.36
发出时间: 15 Feb 2024 @ 02:54
回报率: 23.10%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 4.19 %
Live Chart Being Loaded With Signals
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis...
Stats | |
---|---|
今日成交量 | 90 723.00 |
平均成交量 | 582 479 |
市值 | 245.38M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.0800 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.45 |
ATR14 | $0.0130 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Machatha Stephen | Sell | 11 537 | Common Stock |
2024-03-11 | Greenberg Bruce | Sell | 13 201 | Common Stock |
2024-04-05 | Perceptive Advisors Llc | Buy | 37 712 | Common Stock |
2024-04-04 | Perceptive Advisors Llc | Buy | 140 281 | Common Stock |
2024-04-03 | Perceptive Advisors Llc | Buy | 309 847 | Common Stock |
INSIDER POWER |
---|
17.42 |
Last 100 transactions |
Buy: 8 132 048 | Sell: 3 580 213 |
音量 相关性
Aldeyra Therapeutics Inc 相关性 - 货币/商品
Aldeyra Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-262 780 (0.00 %) |
EPS: | $-0.640 |
FY | 2023 |
营收: | $0 |
毛利润: | $-262 780 (0.00 %) |
EPS: | $-0.640 |
FY | 2022 |
营收: | $0 |
毛利润: | $-258 707 (0.00 %) |
EPS: | $-1.050 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。